<DOC>
	<DOC>NCT00759018</DOC>
	<brief_summary>This protocol allows for the treatment of pediatric patients, male and female, between the ages of 2 months and 17 years. Patients must have failed steroid treatment for Grade B-D acute GVHD.</brief_summary>
	<brief_title>Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD</brief_title>
	<detailed_description>For the treatment of pediatric patients who have failed to respond to steroid treatment for acute graft-versus-host disease (GVHD). Failing steroid treatment for acute GVHD is defined as any Grade B-D (IBMTR grading) of acute GVHD that is not improving after at least 3 days of methylprednisolone (â‰¥ 1 mg/kg/day) or equivalent. Patients will be treated with Prochymal twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<criteria>Patients must be 2 months to 17 years of age, inclusive Patients who have failed to respond to steroid treatment for Grades BD acute GVHD Patient must not have a known allergy to bovine or porcine products Patient must not have received a transplant for a solid tumor disease. Patient must not have evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and is likely to require more than 2L of oxygen via face mask or an estimated FiO2 of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>GVHD</keyword>
	<keyword>Prochymal</keyword>
	<keyword>Graft vs Host Disease</keyword>
</DOC>